View Cart  

EMA Guideline Recommends Placebo Arms for Short-Term Trials of Schizophrenia Drugs

The European Medicines Agency (EMA) is advising sponsors to use placebo arms, rather than active comparators, in short-term trials of schizophrenia drugs, according to a final guidance.

To View This Article:


Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00